The company holds an exclusive license for plant cell-extraction and replication technology used to produce cannabinoids, including THC and CBD, across North America, Central America, and the Caribbean. This technology replicates the flavor, aroma, and potency of cannabis cells within laboratory bioreactors, which removes the need to cultivate entire plants. The company intends to sublicense this proprietary technology and related media culture formulations to third-party cannabis operators. In this model, sublicensees pay fees or royalties while bearing the capital costs of building and running production facilities. The company argues its bioreactor process provides a cost advantage over traditional greenhouse and indoor cultivation by delivering predictable, contamination-free output. However, the company currently has no active operations and has not achieved commercial sales. Commercialization efforts ceased in January 2025 after all officers and directors resigned. As of mid-2026, the company employs only one person. It faces major obstacles, including the loss of its laboratory equipment to creditors and a regulatory framework that favors plant-based cultivation over laboratory extraction. Internal governance issues, such as persistent board deadlocks, and a lack of financing have prevented the company from scaling its technology to a commercial level.